Pharmaceutics (Oct 2022)

Development of Multilayer Nanoparticles for the Delivery of Peptide-Based Subunit Vaccine against Group A <i>Streptococcus</i>

  • Jolynn Kiong,
  • Ummey Jannatun Nahar,
  • Shengbin Jin,
  • Ahmed O. Shalash,
  • Jiahui Zhang,
  • Prashamsa Koirala,
  • Zeinab G. Khalil,
  • Robert J. Capon,
  • Mariusz Skwarczynski,
  • Istvan Toth,
  • Waleed M. Hussein

DOI
https://doi.org/10.3390/pharmaceutics14102151
Journal volume & issue
Vol. 14, no. 10
p. 2151

Abstract

Read online

Peptide-based subunit vaccines include only minimal antigenic determinants, and, therefore, are less likely to induce allergic immune responses and adverse effects compared to traditional vaccines. However, peptides are weakly immunogenic and susceptible to enzymatic degradation when administered on their own. Hence, we designed polyelectrolyte complex (PEC)-based delivery systems to protect peptide antigens from degradation and improve immunogenicity. Lipopeptide (LCP-1) bearing J8 B-cell epitope derived from Group A Streptococcus (GAS) M-protein was selected as the model peptide antigen. In the pilot study, LCP-1 incorporated in alginate/cross-linked polyarginine-J8-based PEC induced high J8-specific IgG antibody titres. The PEC system was then further modified to improve its immune stimulating capability. Of the formulations tested, PEC-4, bearing LCP-1, alginate and cross-linked polylysine, induced the highest antibody titres in BALB/c mice following subcutaneous immunisation. The antibodies produced were more opsonic than those induced by mice immunised with other PECs, and as opsonic as those induced by antigen adjuvanted with powerful complete Freund’s adjuvant.

Keywords